Table 2. Odds ratios (OR) for Kaposi's sarcoma according to a measure of latent and lytic anti-KSHV antibody titre.
|
Unadjusted
|
Adjusted for CD4 counta
|
|||
|---|---|---|---|---|
| Titre | Number of cases/controls N=189 | OR (95% CI) | Number of cases/controls N=163 | OR (95% CI) |
| Latent anti-KSHV antibodies | ||||
| Negative | 117/166 | 1.0 | 99/142 | 1.0 |
| 100–1600 | 27/11 | 3.9 (1.7–9.1) | 25/10 | 3.5 (1.4–8.7) |
| 3200–25 600 | 32/9 | 5.3 (2.3–12.5) | 27/9 | 4.1 (1.7–10.2) |
| 51 200+ | 13/3 | 5.7 (1.5–20.9) | 12/2 | 8.7 (1.9–40.4) |
| χ 2 (1)=32, P<0.001 | χ 2 (1)=26, P<0.001 | |||
|
Unadjusted
|
Adjusted for CD4 countc
|
|||
|---|---|---|---|---|
| Optical densityb (OD) | Number of cases/controls N=187 | OR (95% CI) | Number of cases/controls N=161 | OR (95% CI) |
| Lytic anti-KSHV antibodies | ||||
| Negative | 126/151 | 1.0 | 109/128 | 1.0 |
| Low OD | 18/10 | 2.2 (1.0–5.2) | 14/10 | 1.2 (0.5–3.1) |
| Medium OD | 26/13 | 2.5 (1.2–5.1) | 24/12 | 2.8 (1.3–6.3) |
| High OD | 17/13 | 1.4 (0.7–2.9) | 14/11 | 1.4 (0.6–3.2) |
| χ2(1)=6.2, P=0.02 | χ2(1)=4.3, P=0.04 | |||
a
Adjusted for CD4 count (<200, 200–500, 500+); the number of participants is fewer because some did not have a CD4 count available from around the time the blood was collected.
b
Negative–optical density (OD) <0.84; low OD 0.84–1.06; medium OD 1.07–1.99 and high OD 2.0+.
c
Adjusted for CD4 count (<200, 200–500, 500+).